Global PDGFR Inhibitors Market, Drug Sales and Clinical Trials Insight 2026 Report Analysis and Data Highlights.
Global PDGFR Inhibitors Market, Drug Sales and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 (Qinlock and Ayvakit)
- Approved PGDFR Drug Patent, Price and Sales insight 2020 Till 2026
- Future market Assessment By Indication and Region Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
Platelet derived growth factor receptor (PDGFR) belongs to platelet deriver growth factor family and is a tyrosine kinase. There are two types of platelet-derived growth factor receptor encoded by different gene i.e. platelet-derived growth factor receptor alpha and -beta. PDGFRα signaling controls the development of embryonic early phase and of several organs such as skin, bones, lung, kidney, intestine, testis and neuroprotective tissues whereas PDGFRβ signaling is an essential regulator for blood vessel formation and early hematopoiesis. Apart from this, several studies have demonstrated that PDGFR signaling pathway also has a critical role in cancer development, therefore emerging as potential therapeutic target.
Ayvakit developed by Blueprint Medicine was the first PDGFR inhibitor to gain entry into the market. The drug is approved by regulatory bodies for two therapeutic indications include adults with advanced systemic mastocytosis and adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Later, Deciphera Pharmaceutical also announced the approval of Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. Qinlock is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.
The raqpid approval of these drugs in 2021 and robust response rate in short span of time has spurred the further research and development activities in this sector. The pipeline for novel PDGFR inhibitor consists of several potential candidates including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001 which are present in early stages of clinical trial. Apart from cancer, researchers are also evaluating the role in other therapeutic indications which will also boost the growth of market. For example, Seralutinib (GB-002) developed by Gossamer Bio is inhaled PDGFR, CSF1R and c-KIT Inhibitor being evaluated for Pulmonary Arterial Hypertension (PAH).
To further enhance the efficacy of treatment, researchers are evaluating the role of PDGFR inhibitors in combination with other cancer targeting drugs. For instance in 2022, Akeso entered into a collaboration agreement with Shenzhen Chipscreen Biosciences to conduct a phase-Ib/II clinical trial for the study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L)1 inhibitor as first-line treatment.
As per our report findings, the global PDGFR inhibitor market is expected to surpass US$ 4 Billion by 2028. The growth of the global market is attributed to factors such as the growing prevalence of cancer and other chronic diseases, and strong investment in research and development activities by key market players. Blueprint Medicines and Deciphera Pharmaceuticals are the leaders in the PDGFR kinase inhibitor market. Companies are investing in research to deal with issues such as resistance, selectivity vs. safety, developing lead compounds, integrating chemistry and biology into development, and utilizing the newest techniques, such as fragment- and structure-based design, to develop new products.
The report provides comprehensive analysis on the commercial information of available PDGFR inhibitor including patent, pricing, dosage, and sales analysis. The report includes estimation of the market size and analyses of global market trends, with data from 2019, 2020, and 2021 and projections of compound annual growth rates (CAGRs) through 2028. The report also identifies market drivers, restraints and other forces impacting the global market. The major companies mentioned in the report are AstraZeneca. Clovis Oncology, Bayer, Blueprint Medicine, Zai Lab, Pfizer, Gilead Sciences, Deciphera Pharmaceuticals, and several others.
Contact:
Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+91-9810410366